Recommended Articles
Fundraising

OMass Therapeutics Raises $310M Series C to Advance Endocrinology Pipeline

By Angeled · October 17, 2026 · Fundraising
OMass Therapeutics Raises $310M Series C to Advance Endocrinology Pipeline
OMass Therapeutics Raises $310M Series C to Advance Endocrinology Pipeline

OMass Therapeutics, an Oxford, UK-based biotechnology company, announced on October 15, 2026 an oversubscribed $310 million (£230 million) Series C financing to advance its portfolio of small molecule therapeutics in endocrinology and immunology. It is one of the largest European biotech rounds of the year.

The deal

  • Company: OMass Therapeutics (Oxford, United Kingdom)
  • Round: $310M (£230M) oversubscribed Series C
  • Co-led by: new investors Bain Capital Life Sciences, Forbion, and Novo Holdings
  • New participants: Janus Henderson Investors, SV Health Investors, Jefferson Life Sciences
  • Existing investors: Syncona, Oxford Science Enterprises, GV, Northpond Ventures, Sanofi Ventures, British Business Bank, University of Oxford — all participated
  • Prior funding: $100M Series B in 2022, topped off with an additional £10M in 2023

What the money funds

The proceeds advance the company's lead program, OMS1620 — a potential best-in-class MC2 (melanocortin-2) receptor antagonist — through Phase 2 clinical development in two indications:

  1. Congenital adrenal hyperplasia (CAH) — a group of inherited genetic disorders affecting the adrenal glands' ability to produce cortisol
  2. ACTH-dependent Cushing's syndrome — a rare disorder caused by excess adrenocorticotropic hormone driving cortisol overproduction

OMS1620 is designed to increase receptor residency time and remain active in the presence of rising endogenous ACTH levels, which could allow more CAH patients to achieve androgen normalization while on physiologic doses of glucocorticoids.

The financing also supports the earlier-stage pipeline, including generating initial clinical data for a potential first-in-class SLC15A4 inhibitor for lupus and other diseases associated with interferon overproduction and pathogenic B-cell activation.

The technology platform

OMass originated from research in Professor Dame Carol Robinson's laboratory at the University of Oxford. Its drug-discovery platform combines native mass spectrometry, specialized biochemistry, and chemistry techniques to study proteins and their interactions in biologically relevant environments — aimed at finding medicines for targets that have historically been hard to drug.

The company describes itself as developing small molecule therapeutics "against highly validated target ecosystems," a framing that has clearly resonated with crossover investors entering the round.

Why it matters: UK biotech in 2026

OMass has stated ambitions to become "Britain's Big Biotech" — the UK's answer to success stories like Vertex or Genentech. A $310M oversubscribed Series C, co-led by three heavyweight life-sciences investors with broad crossover participation, is the strongest signal yet that the UK can still produce biotech rounds at global scale.

For founders and investors watching European life sciences:

  • Mega-rounds are back. After the biotech funding contraction of 2022–2024, 2026 has seen capital concentrate in platform companies with clinical-stage assets. OMass, now advancing OMS1620 through Phase 1 into Phase 2, fits the pattern.
  • Sovereign and academic capital de-risks early. The University of Oxford and British Business Bank's presence in the syndicate reflects how UK biotech ecosystems still lean on public and institutional anchors to get to scale.
  • Rare endocrine indications attract generalists. Janus Henderson's participation alongside specialist biotech VCs shows that well-designed small-molecule programs in validated pathways can pull in crossover money even before pivotal data.

The question for the rest of the UK biotech sector is whether OMass becomes the template — or the exception.

Angeled.com connects founders with investors.

Sources: reported October 15–16, 2026 — company announcement via Axcess News syndication; Fierce Biotech Fundraising Tracker 2026.

Read Next